Purified human basophils and mast cells: current concepts of mediator release. 1983

E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein

Mediators released from human basophils and mast cells in response to immunologic and other stimuli are felt to be important in the pathophysiology of several nasal and pulmonary disease processes. Recently, we have developed techniques to purify these cells, thus allowing precise ultrastructural, biochemical and pharmacological studies of mediator release. Previous literature has emphasized the similarities of the two cell types including their metachromatic staining and IgE-mediated release of mediators. However, we now appreciate that several differences exist between the two cell types. At the ultrastructural level, basophil release is characterized by individual granules emptying to the cell exterior, while mast cell granules fuse intracellularly and release their contents through cytoplasmic channels. Functionally, basophils are 10- to 30-fold more sensitive than mast cells to anti-IgE, but the kinetics of release are less rapid. Basophil, but not mast cell, release is (I) inhibited by histamine H2 agonists and glucocorticoids; (II) enhanced by PgD2 and (III) modulated by arachidonic acid lipoxygenase metabolites. Significant quantities of slow-reacting substance of anaphylaxis, PgD2 and platelet-activating factor are generated by mast cells. Basophils produce little or none of these mediators. Studies with these purified, relevant human cell types should provide important insights into the cellular basis of hypersensitivity states and their control.

UI MeSH Term Description Entries
D008407 Mast Cells Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR. Basophils, Tissue,Basophil, Tissue,Cell, Mast,Cells, Mast,Mast Cell,Tissue Basophil,Tissue Basophils
D011457 Prostaglandins D Physiologically active prostaglandins found in many tissues and organs. They show pressor activity, are mediators of inflammation, and have potential antithrombotic effects. PGD
D002469 Cell Separation Techniques for separating distinct populations of cells. Cell Isolation,Cell Segregation,Isolation, Cell,Cell Isolations,Cell Segregations,Cell Separations,Isolations, Cell,Segregation, Cell,Segregations, Cell,Separation, Cell,Separations, Cell
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001491 Basophils Granular leukocytes characterized by a relatively pale-staining, lobate nucleus and cytoplasm containing coarse dark-staining granules of variable size and stainable by basic dyes. Basophil
D013189 SRS-A A group of LEUKOTRIENES; (LTC4; LTD4; and LTE4) that is the major mediator of BRONCHOCONSTRICTION; HYPERSENSITIVITY; and other allergic reactions. Earlier studies described a "slow-reacting substance of ANAPHYLAXIS" released from lung by cobra venom or after anaphylactic shock. The relationship between SRS-A leukotrienes was established by UV which showed the presence of the conjugated triene. (From Merck Index, 11th ed) Slow Reacting Substance of Anaphylaxis
D013929 Thromboxane B2 A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin). B2, Thromboxane
D015230 Prostaglandin D2 The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. 11-Dehydroprostaglandin F2alpha,PGD2,11-Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2alpha,D2, Prostaglandin,F2 alpha, 11-Dehydroprostaglandin,F2alpha, 11-Dehydroprostaglandin,alpha, 11-Dehydroprostaglandin F2

Related Publications

E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
January 1988, Immunological investigations,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
January 1987, International archives of allergy and applied immunology,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
January 1986, Respiration; international review of thoracic diseases,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
February 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
October 1984, The Journal of allergy and clinical immunology,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
January 1985, International archives of allergy and applied immunology,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
October 1984, Federation proceedings,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
April 1986, The American review of respiratory disease,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
November 1995, International archives of allergy and immunology,
E S Schulman, and D W MacGlashan, and R P Schleimer, and S P Peters, and A Kagey-Sobotka, and H H Newball, and L M Lichtenstein
January 1990, Biochemical pharmacology,
Copied contents to your clipboard!